CPC A61K 31/7068 (2013.01) [A61K 31/455 (2013.01); A61K 45/06 (2013.01)] | 5 Claims |
1. A method for treating a tumor, including administering cytarabine and a dihydroorotate dehydrogenase inhibitor compound to a subject,
wherein the tumor cells are cytarabine-resistant leukemia cells; and
the dihydroorotate dehydrogenase inhibitor compound is at least one or more compounds selected from the group consisting of Brequinar, Vidofludimus, Teriflunomide, Leflunomide, N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl]-5-fluoro-2-{[(2 S)-1,1,1-trifluoropropan-2-yl] oxy} benzamide, (S)-4-chlorophenyl 6-chloro-1-(4-hydroxyphenyl)-3,4-dihydro-1H-pyrido[3,4-b]indol-2 (9H)-carboxylate, and a compound represented by General Formula (1), or a salt thereof,
in the formula,
G1 is a CH or nitrogen atom;
R1 is a hydrogen atom, a halogen atom, a C1-6 alkyl group which may be substituted, or a C3-8 cycloalkyl group which may be substituted; and
R2 is an aryl group which may be substituted or a bicyclic heterocyclic group which may be substituted, or
the dihydroorotate dehydrogenase inhibitor compound is at least one or more compounds selected from the group consisting of ASLAN003 (2-((3,5-difluoro-3′-methoxybiphenyl-4-yl)amino) nicotinic acid) and 5-cyclopropyl-2-((1-phenyl-1H-indol-5-yl)amino) nicotinic acid, or a salt thereof.
|